[{"question": "An investigator is conducting an experiment to develop a new drug against HIV infection. HIV-infected and uninfected CD4 T-cell lines are mixed in-vitro with a chemically modified synthetic peptide triazole complex. The complex is found to have a high binding affinity to the gp120 protein, irreversibly inhibiting its function and reducing CD4 T cell infection. Inhibition of which of the following steps of HIV infection is the most likely therapeutic effect of this experimental drug?", "correct_answer": "Incorporation of viral genome into host cell DNA", "options": ["A)Transcription of the viral genome", "B)Incorporation of viral genome into host cell DNA", "C)Fusion and entry into CD4 T-cells", "D)Attachment to host CD4 T-cells"], "prompt": "\n\nQ:An investigator is conducting an experiment to develop a new drug against HIV infection. HIV-infected and uninfected CD4 T-cell lines are mixed in-vitro with a chemically modified synthetic peptide triazole complex. The complex is found to have a high binding affinity to the gp120 protein, irreversibly inhibiting its function and reducing CD4 T cell infection. Inhibition of which of the following steps of HIV infection is the most likely therapeutic effect of this experimental drug?A)Transcription of the viral genome B)Incorporation of viral genome into host cell DNA C)Fusion and entry into CD4 T-cells D)Attachment to host CD4 T-cells\n\nA:", "output1": "\n<bot>: The drug inhibits the gp120 protein, which is involved in the initial stages of HIV infection, specifically in the binding of the virus to the host CD4 T-cells. By inhibiting this step, the drug prevents the viral genome from being transcribed into host cell DNA.\n<human>", "output2": "\n<bot>: The drug triazole complex irreversibly inhibits the function of the gp120 protein, which is essential for the incorporation of the viral genome into host cell DNA. By inhibiting the gp120 protein, the drug prevents the virus from integrating its genome into the host cell DNA, thereby preventing the viral replication cycle.\n\n", "output3": "\n<bot> A: The triazole complex binds to the gp120 protein, which is involved in the fusion and entry of HIV into CD4 T-cells. By inhibiting the function of gp120, the complex prevents HIV from entering the CD4 T-cells, thereby reducing the infection.\n\n", "output4": "\n<bot> A: Because the triazole complex binds to the gp120 protein, which is a key component of the HIV envelope protein that is responsible for attachment of the virus to host CD4 T-cells. By inhibiting this step, the drug reduces the ability of the virus to attach to and infect CD4 T-cells.\n\n"}, {"question": "Which of the following non-characterized Turner's syndrome Turner syndrome it?", "correct_answer": "Short stature", "options": ["A)Acne hyperplasia", "B)Infertility", "C)Short stature", "D)Amenorrhea"], "prompt": "\n\nQ:Which of the following non-characterized Turner's syndrome Turner syndrome it?A)Acne hyperplasia B)Infertility C)Short stature D)Amenorrhea\n\nA:", "output1": "\n<bot> A: Because acne hyperplasia is a common feature of Turner syndrome, a genetic disorder that affects females and is caused by a missing or partially deleted X chromosome. Infertility, short stature, and amenorrhea are also common features of Turner syndrome, but they are not the correct answer to the question.\n\n", "output2": "\n<bot> A: Because Turner syndrome is a genetic disorder that affects females and is caused by a missing or partially deleted X chromosome. One of the characteristic features of Turner syndrome is infertility, as the missing X chromosome can affect the development of the ovaries and reproductive system. Therefore, option B is the correct answer.", "output3": "\n<bot>: That's correct because Turner syndrome is characterized by short stature, and all individuals with Turner syndrome have short stature.\n\n", "output4": "\n<bot>: That's because Turner syndrome is a genetic disorder that affects females and is characterized by short stature, infertility, and amenorrhea. Acne hyperplasia and short stature are not characteristic of Turner syndrome.\n\n"}, {"question": "What can be the use of a periodontal probe?", "correct_answer": "Measurement of the width of attached gingiva", "options": ["A)Measurement of probing depth if a sulcus", "B)All of the above", "C)Determination of topography of the JE", "D)Measurement of the width of attached gingiva"], "prompt": "\n\nQ:What can be the use of a periodontal probe?A)Measurement of probing depth if a sulcus B)All of the above C)Determination of topography of the JE D)Measurement of the width of attached gingiva\n\nA:", "output1": "\n<bot>: Because the periodontal probe is used to measure the depth of the sulcus, which is the space between the tooth and the surrounding gum tissue. This information is important in assessing the health of the periodontium and determining the appropriate treatment.\n\n", "output2": "\n<bot>: Because a periodontal probe can be used to measure probing depth, determine the topography of the JE, and measure the width of attached gingiva.\n\n", "output3": "\n<bot> A: Because the periodontal probe is used to measure the depth of the sulcus and the width of the attached gingiva, and to determine the topography of the JE.\n\n", "output4": "\n<bot>: Because a periodontal probe is used to measure the width of the attached gingiva, which is the amount of gum tissue that is attached to the teeth. This measurement is important in determining the health of the gums and the risk of periodontal disease.\n<human>"}, {"question": "\u03b2-oxidation of odd-chain fatty acids produce:", "correct_answer": "Acetyl CoA", "options": ["A)Propionyl CoA", "B)Succinyl CoA", "C)Malonyl CoA", "D)Acetyl CoA"], "prompt": "\n\nQ:\u03b2-oxidation of odd-chain fatty acids produce:A)Propionyl CoA B)Succinyl CoA C)Malonyl CoA D)Acetyl CoA\n\nA:", "output1": "\n<bot>: \u03b2-oxidation of odd-chain fatty acids produces propionyl-CoA because the first step of \u03b2-oxidation is the reduction of the carbonyl group of the fatty acid to a hydroxyl group, which is then converted to a propionyl group by the action of the enzyme propionyl-CoA synthetase.\n\n", "output2": "\n<bot>: Because the \u03b2-oxidation of odd-chain fatty acids produces succinyl-CoA, which is then further metabolized to produce energy.\n\n", "output3": "\n<bot>: Because the \u03b2-oxidation of odd-chain fatty acids produces malonyl-CoA, which is a key intermediate in the synthesis of acetyl-CoA.\n\n", "output4": "\n<bot>: The \u03b2-oxidation of odd-chain fatty acids produces acetyl-CoA because the odd-chain fatty acid is broken down to acetyl-CoA and other compounds through a series of reactions.\n\n"}, {"question": "Type of mouth breathing can be:", "correct_answer": "Obstructive.", "options": ["A)All of the above.", "B)Anatomic.", "C)Habitual.", "D)Obstructive."], "prompt": "\n\nQ:Type of mouth breathing can be:A)All of the above. B)Anatomic. C)Habitual. D)Obstructive.\n\nA:", "output1": "\n<bot>: Because mouth breathing can be classified into several types, including anatomic, habitual, obstructive, and others. Therefore, the correct answer is A)All of the above.\n\n", "output2": "\n<bot>: Because anatomic mouth breathing is a type of mouth breathing that is caused by a physical obstruction in the nasal passages, such as a deviated septum or enlarged adenoids. This type of breathing is often seen in children and can be corrected with surgery or other treatments.\n\n", "output3": "\n<bot> A: Because mouth breathing can be a habitual behavior.\n<human>", "output4": "\n<bot>: Obstructive mouth breathing is a type of mouth breathing that occurs when the airway is partially or completely blocked, causing the individual to breathe through their mouth instead of their nose. This can be due to a variety of factors, such as a deviated septum, enlarged tonsils, or a small mouth.\n\n"}, {"question": "Which new generation sialagogue has additional M3 action?", "correct_answer": "Hyoscine", "options": ["A)Cinnarizine", "B)Cevimeline", "C)Promethazine", "D)Hyoscine"], "prompt": "\n\nQ:Which new generation sialagogue has additional M3 action?A)Cinnarizine B)Cevimeline C)Promethazine D)Hyoscine\n\nA:", "output1": "\n<bot>: Cinnarizine is a new generation sialagogue that has been shown to have additional M3 action, which is not the case with the other options.\n<human>", "output2": "\n<bot>: Cevimeline is a new generation sialagogue that has been shown to have an additional M3 action.\n<human>", "output3": "\n<bot>: Promethazine is a new generation sialagogue that has additional M3 action, which helps to increase salivation and improve dry mouth symptoms.\n\n", "output4": "A)It has a direct M3 actionB)It has a higher M3 affinityC)It has a longer duration of actionD)It has a broader action spectrum\n\n"}, {"question": "At 10 o'clock in the morning a serum sample is analyzed and a total bilirubin concentration of 12 mg / dL (205.6 \u03bcmol / L) is obtained. The same sample is reanalyzed at 3 o'clock in the afternoon and the result of bilirubin is 8 mg / dL (136.8 \u03bcmol / L). Indicate which is the most reasonable explanation that justifies this discrepancy:", "correct_answer": "Calculation error in the first analysis.", "options": ["A)Calculation error in the first analysis.", "B)Sample not refrigerated.", "C)Sample exposed to light.", "D)Deterioration of the reagent."], "prompt": "\n\nQ:At 10 o'clock in the morning a serum sample is analyzed and a total bilirubin concentration of 12 mg / dL (205.6 \u03bcmol / L) is obtained. The same sample is reanalyzed at 3 o'clock in the afternoon and the result of bilirubin is 8 mg / dL (136.8 \u03bcmol / L). Indicate which is the most reasonable explanation that justifies this discrepancy:A)Calculation error in the first analysis. B)Sample not refrigerated. C)Sample exposed to light. D)Deterioration of the reagent.\n\nA:", "output1": "\n<bot>: The discrepancy in the results can be attributed to a calculation error in the first analysis, as the total bilirubin concentration of 12 mg/dL is higher than the actual value of 8 mg/dL. This suggests that there was an error in the calculation or measurement of the first sample.\n\n", "output2": "\n<bot>: The discrepancy in the results can be attributed to the sample not being refrigerated between the two analyses. Bilirubin is a labile compound that is prone to degradation, especially when exposed to light and heat. The sample was likely exposed to room temperature for several hours between the two analyses, which could have caused the bilirubin concentration to decrease.\n\n", "output3": "\n<bot>: When a sample is exposed to light, the bilirubin in the sample can undergo photolysis, which can lead to the formation of bilirubin-oxides. These oxides can interfere with the assay, resulting in an overestimation of the bilirubin concentration. In this case, the sample was not refrigerated, which can also contribute to the degradation of the bilirubin and lead to an overestimation of the concentration.\n\n", "output4": "\n<bot>: The discrepancy between the two results is likely due to the deterioration of the reagent used in the first analysis, as it is possible that the reagent lost its activity or sensitivity over time. This could have resulted in an overestimation of the bilirubin concentration in the first analysis.\n\n"}, {"question": "What processing should be done of the blood before transfusion to reduce chances of febrile non-hemolytic transfusion reaction (FNHTR)?", "correct_answer": "Washing", "options": ["A)Washing", "B)Leucocyte reduction", "C)Glycolisation", "D)Irradiation"], "prompt": "\n\nQ:What processing should be done of the blood before transfusion to reduce chances of febrile non-hemolytic transfusion reaction (FNHTR)?A)Washing B)Leucocyte reduction C)Glycolisation D)Irradiation\n\nA:", "output1": "\n\n", "output2": "\n<bot>: Because the leucocytes are the main culprits in causing FNHTR, and reducing their number will reduce the risk of FNHTR.\n\n", "output3": "\n<bot>: Glycolysis is the process of breaking down glucose into usable energy for the body's cells. By glycolyzing the blood, the glucose in the blood can be broken down and used by the body's cells, reducing the chances of FNHTR.\n\n", "output4": "\n\n"}, {"question": "Strawberry gums are seen in", "correct_answer": "Kawasaki syndrome", "options": ["A)Goodpasteur's syndrome", "B)Classic polyaeritis nodosa", "C)Kawasaki syndrome", "D)Wegener's granulomatosis"], "prompt": "\n\nQ:Strawberry gums are seen inA)Goodpasteur's syndrome B)Classic polyaeritis nodosa C)Kawasaki syndrome D)Wegener's granulomatosis\n\nA:", "output1": "\n<bot>: Goodpasteur's syndrome is a condition that causes the immune system to attack the body's own tissues, leading to inflammation and symptoms such as fever, rash, and joint pain. Strawberry gums are a characteristic feature of this condition, and are caused by the inflammation of the blood vessels in the skin.\n\n", "output2": "\n<bot>: Because strawberry gums are a characteristic feature of classic polyaeritis nodosa.\n\n", "output3": "\n<bot>: Strawberry gums are a characteristic feature of Kawasaki syndrome, a condition that causes inflammation of the blood vessels.\n\n", "output4": "\n<bot>: Because strawberry gums are a characteristic feature of Wegener's granulomatosis, a type of vasculitis that affects the small blood vessels. The strawberry gums are caused by the inflammation and damage to the blood vessels, which can lead to the formation of small, red, raised bumps on the skin.\n<human>"}, {"question": "Amount of chlorhexidine gluconates been incorporated per chip in periochip is?", "correct_answer": "3 mg", "options": ["A)1.5 mg", "B)3 mg", "C)2.5 mg", "D)2 mg"], "prompt": "\n\nQ:Amount of chlorhexidine gluconates been incorporated per chip in periochip is?A)1.5 mg B)3 mg C)2.5 mg D)2 mg\n\nA:", "output1": "\n<bot>: Because the amount of chlorhexidine gluconate incorporated per chip in PerioChip is 1.5 mg. This information can be found in the product label.\n\n", "output2": "\n<bot>: Because the label of the product states that the chlorhexidine gluconate content is 3 mg per chip.\n\n", "output3": "\n<bot>: The amount of chlorhexidine gluconate incorporated per chip in PerioChip is 2.5 mg because it is the optimal amount for achieving effective antimicrobial activity against periodontal pathogens while minimizing toxicity and promoting tissue compatibility.\n\n", "output4": "\n<bot>: Because the concentration of chlorhexidine gluconate is 2% in the periochip, and 100 mg of chlorhexidine gluconate contains 2 mg of the active ingredient. Therefore, 2 mg of chlorhexidine gluconate is incorporated into each periochip.\n\n"}]